

Transgene Announces Upcoming Investor Meetings

Strasbourg, March 27, 2023 - 05:45 pm CET

TRANSGENE (Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that Management will participate in several investor events, as set out below.

- **The Future of Oncology Symposium, Cantor** (virtual): April 3-5, 2023
- **Investor Access Forum**, Paris: April 4-5, 2023
- **Canaccord Genuity Horizons in Oncology Virtual Conference** (virtual): April 20, 2023
- **Kempen Van Lanschot Life Sciences Conference**, Amsterdam: April 25-26, 2023
- **Sachs Annual Immuno-Oncology Innovation Forum**, Chicago: June 2, 2023
- **Stifel European Healthcare Summit**, Bordeaux: June 28-30, 2023

In addition, Transgene will host a booth (#310) and present several posters at the **American Association for Cancer Research (AACR) Annual Meeting**, which will take place in Orlando, Florida, USA, April 14 – 19, 2023.

About Transgene

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

The Company's clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses: TG4050, the first individualized therapeutic vaccine based on the *myvac*[®] platform, TG4001 for the treatment of HPV-positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO[®] viral backbone. With Transgene's *myvac*[®] platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The *myvac*[®] approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.

With its proprietary platform Invir.IO[®], Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO[®] collaboration with AstraZeneca. Additional information about Transgene is available at: www.transgene.fr

Follow us on Twitter: [@TransgeneSA](https://twitter.com/TransgeneSA)

Contacts

Transgene:
Lucie Larguier
Director Corporate Communications & IR
+33 (0)3 88 27 91 04
investorrelations@transgene.fr

Media: MEDiSTRAVA Consulting
David Dible/Sylvie Berrebi/George Underwood
+44 (0)203 928 6900
transgene@medistrava.com



Disclaimer

This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document, available on the AMF website (<http://www.amf-france.org>) or on Transgene's website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.